Chinese Cell And Gene Therapies Enjoy Limelight Amid Summer Fundraising Lull
Executive Summary
CorrectSequence led the pack of Chinese cell and gene therapy developers seeking new funding with a roughly $14m series A-plus round. In other modalities, antibody-focused developers Mabgeek and Novamab closed series Bs.